Soluble complement receptor 1 (sCR1) protects against experimental autoimmune myasthenia gravis
- 31 December 1996
- journal article
- Published by Elsevier BV in Journal of Neuroimmunology
- Vol. 71 (1-2), 173-177
- https://doi.org/10.1016/s0165-5728(96)00144-0
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Blockade of Complement Activation Prevents Local and Pulmonary Albumin Leak After Lower Torso Ischemia—ReperfusionAnnals of Surgery, 1992
- Passive transfer of experimental myasthenia gravis via antigenic modulation of acetylcholine receptorEuropean Journal of Immunology, 1992
- Acetylcholine receptor gene expression in experimental autoimmune myasthenia gravisFEBS Letters, 1990
- Soluble Human Complement Receptor Type 1: In Vivo Inhibitor of Complement Suppressing Post-Ischemic Myocardial Inflammation and NecrosisScience, 1990
- Humoral Pathogenesis of Myasthenia GrayisaAnnals of the New York Academy of Sciences, 1987
- The Membrane Attack Complex of Complement at the Endplate in Myasthenia GravisaAnnals of the New York Academy of Sciences, 1987
- Acetylcholine receptor antibody as a diagnostic test for myasthenia gravis: results in 153 validated cases and 2967 diagnostic assays.Journal of Neurology, Neurosurgery & Psychiatry, 1985
- Acetylcholine receptor turnover in mice with passively transferred myasthenia gravis. II. Receptor synthesis.Journal of Neurology, Neurosurgery & Psychiatry, 1983
- MONOCLONAL AUTOANTIBODIES TO ACETYLCHOLINE RECEPTORS: EVIDENCE FOR A DOMINANT IDIORPE AND REQUIREMENT OF COMPLEMENT FOR PATHOGENICITY*Annals of the New York Academy of Sciences, 1981
- Pathological mechanisms in experimental autoimmune myasthenia gravis. I. Immunogenicity of syngeneic muscle acetylcholine receptor and quantitative extraction of receptor and antibody-receptor complexes from muscles of rats with experimental automimmune myasthenia gravis.The Journal of Experimental Medicine, 1976